ESTRO 2022 - Abstract Book

S1218

Abstract book

ESTRO 2022

Conclusion Through this hypothesis-generating study, we demonstrated the prognostic value of baseline tumor burden and metastasis locations in metastatic melanoma patients receiving pembrolizumab. Our results are helpful for better risk stratifying and designing clinical study which refines the role of RT in combination with immunotherapy.

PO-1436 Radical radiotherapy for non-melanoma skin cancer: orthovoltage vs. electronic brachytherapy

M. Cerrolaza 1 , P. Sanagustin 1 , V. Navarro 1 , C. Escuin 1 , A. Lanuza 1 , S. Flamarique 1 , A. Campos 1 , M. Lanzuela 1 , R. Ibañez 1 , M. Tejedor 1

1 University Hospital Miguel Servet, Radiotherapy, ZARAGOZA, Spain

Purpose or Objective Non melanoma skin cancer is the most frequent malignancy worldwide. Its development is related to age, high exposure to ultraviolet rays, fair skin and immunosuppression. Eighty percent usually occur in areas of the head and neck and are mostly basal cell carcinomas and squamous cell carcinomas. Surgery is usually the treatment of choice, however, radiotherapy is an effective option in patients who are not candidates for surgical resection due to comorbidities, age, location or post-surgical morbidity. Our aim has been to evaluate the differences in effectiveness and toxicity between two types of superficial radiotherapy treatments: low energy photons and electronic brachytherapy. Materials and Methods Patients with non-melanoma skin cancer treated with superficial radiotherapy with radical intent between October 2019 and June 2021 were retrospectively collected. Treatment was administered by low-energy photons using Therapax 150 orthovoltage devices or 50 Kv X-rays using the Axxent Xoft device (electronic surface brachytherapy). Demographic and anatomopathologic data, as well as treatment characteristics, toxicities (CTCAE V5) and observed results were compared between both groups. Student's T was used for quantitative variables and chi-square for qualitative variables with p<0.05 being considered as statistically significant differences.